GET DAILY SIGNALSOrthofix Medical (OFIX): Analyst Consensus Points to a $13 Target with +65% Upside
Key Takeaways
- The central target of $13 is the arithmetic mean of four verified analyst price targets from Canaccord Genuity, Barrington Research, Stifel, and TD Cowen.
- At a recent price near $7.87, reaching $13 would require roughly 65% upside, a substantial move for this small-cap medical technology company.
- The analyst target range spans from a low of $12 to a high of $14, with three Buy ratings and one Hold.
- Key positive factors include differentiated products like the 7D FLASH navigation system, the VIRATA spinal implant launch, and growth in limb reconstruction.
- Major risks involve weak U.S. spine demand, a recently lowered full-year revenue outlook, negative free cash flow, and roughly $118 million in net debt.
Analyst Price Targets and Consensus View
Orthofix Medical Inc. (OFIX), a global spine and orthopedics company, draws coverage from a limited group of sell-side analysts. The most recent verifiable targets include Canaccord Genuity at $13 (Buy), Barrington Research at $14 (Outperform), Stifel at $13 (Buy), and TD Cowen at $12 (Hold). The arithmetic mean of these four targets stands at $13.00, with the range running from $12 to $14.
This set of targets reflects a year of steady downward revisions. Earlier in 2026, several firms carried targets in the high teens to low $20s, but those were trimmed repeatedly as U.S. spine demand softened and the company adjusted guidance. The spread between the lowest and highest targets remains tight, indicating broad agreement on near-term earnings power while views differ modestly on execution risk. No single target serves as a guarantee, and the mean is simply a calculated figure rather than an official consensus.
Current Market Position and Path Toward the Target
OFIX recently traded near $7.87, just above its 52-week low of $7.81 and well below its 52-week high of $16.42. Reaching the $13 central target would require an increase of roughly 65%, a sizable move that would bring the shares back toward the upper end of their recent trading range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company reported third-quarter 2026 results with revenue of about $207.9 million, up only 1.1% year over year, while cutting full-year revenue guidance to roughly $825 million to $830 million and trimming its adjusted EBITDA outlook. With a market capitalization near $320 million, negative free cash flow, and net debt of about $118 million, any path toward $13 hinges on genuine stabilization and re-acceleration of the U.S. spine franchise rather than isolated quarterly improvement.
What Could Support a Move Toward the Target
- Differentiated technology: The 7D FLASH navigation system, positioned as a zero-radiation intraoperative platform, and the planned full launch of the VIRATA spinal implant system could drive adoption and cross-selling.
- Growth outside U.S. spine: Global limb reconstruction and therapeutic solutions have shown above-market momentum, with products such as FITBONE and TRUELOK Elevate.
- Biologics stabilization: Management noted signs of stabilization in U.S. biologics, including a return to year-over-year growth in October.
- Restructuring focus: Consolidating distribution around higher-performing partners and simplifying the portfolio could improve channel productivity and cash conversion over time.
What Could Prevent the Target From Being Reached
- U.S. spine weakness and execution risk: Supplier delays and inventory constraints have created near-term sales pressure, and the turnaround plan will take multiple quarters.
- Reimbursement pressure: A Medicare reimbursement reset affecting stimulator products has weighed on revenue and could persist.
- Balance-sheet constraints: Negative free cash flow and net debt leave limited margin to absorb another guidance miss or slower adoption of new products.
- Analyst revision risk: The most recent targets predate the November guidance cut, so further downward revisions remain possible.
Technical Levels and Market Structure
The shares sit near their 52-week low of $7.81, which stands as the most important near-term support level; a decisive break below it would place the stock at multiyear lows. On the upside, the $10 level represents a psychological round-number hurdle, followed by resistance near $12 to $14, where current analyst targets cluster. OFIX trades below both its 50-day and 200-day moving averages, pointing to a firmly negative longer-term trend structure that would need to reverse for the $13 target to become realistic.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. The most important upcoming catalysts include the pace of the VIRATA launch, the execution of the U.S. spine distribution consolidation, quarterly free cash flow progress, and any further guidance updates. Investors should also watch for analyst target revisions following the recent revenue cut, Medicare reimbursement developments, and the company’s progress toward positive free cash flow.
Using AI Daily Buy/Sell Signals in Practice
For traders seeking a more systematic view, I have found Tickeron’s AI Daily Buy/Sell Signals helpful in monitoring stocks like OFIX. These signals draw on artificial intelligence to track thousands of stocks and ETFs continuously, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. They can support discovery of opportunities, tracking of existing positions, and identification of trend changes more efficiently than manual methods alone.
Final Assessment
The $13 central target represents the calculated mean of four analyst price targets, not a forecast or guarantee, and it implies a very large move of roughly 65% from the current price near $7.87. The bull case rests on differentiated technology, growth outside U.S. spine, and a restructuring plan aimed at improving execution and cash flow. The bear case centers on persistent U.S. spine weakness, reimbursement headwinds, a trimmed outlook, and a leveraged balance sheet with negative free cash flow. With analysts clustered between $12 and $14 but largely issuing Buy ratings, the debate centers less on direction than on the timing and credibility of a turnaround. Investors should monitor the VIRATA launch, free cash flow trajectory, and any analyst revisions before drawing conclusions about whether OFIX can reach $13.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OFIX in downward trend: 10-day moving average moved below 50-day moving average on November 06, 2026
The 10-day moving average for OFIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OFIX as a result. In 71 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for OFIX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 43 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
OFIX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OFIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where OFIX advanced for three days, in 202 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
OFIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 117 of 149 cases where OFIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. OFIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.747) is normal, around the industry mean (4.142). P/E Ratio (-5.178) is within average values for comparable stocks, (3.291). OFIX's Projected Growth (PEG Ratio) (48.825) is slightly higher than the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.431) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OFIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of surgical products to the spine and orthopedic markets
Industry MedicalNursingServices
Advertisement